Atlas Trials

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Clinical trial NCT02807558 · COMPLETED

Trial details

NCT number
NCT02807558
Sponsor
Syros Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Start date
2016-09-20
Primary completion
2023-01-25
Enrollment
155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.